| Project/Area Number |
15H04827
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
NOGUCHI Emiko 筑波大学, 医学医療系, 教授 (40344882)
TAMARI Mayumi 東京慈恵会医科大学, 総合医科学研究センター, 教授 (00217184)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥17,810,000 (Direct Cost: ¥13,700,000、Indirect Cost: ¥4,110,000)
Fiscal Year 2017: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2016: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥9,360,000 (Direct Cost: ¥7,200,000、Indirect Cost: ¥2,160,000)
|
|---|
| Keywords | Endotype / Phenotype / Asthma / COPD / Precision medicine / CDHR3 / YKL-40 / Tyro3 / 喘息 / TYRO3 / エンドタイプ / フェノタイプ / 遺伝因子 / 遺伝子 |
|---|
| Outline of Final Research Achievements |
Identification of genetic factors associated with severe airway diseases allows us to understand the pathogenesis of diseases and to implement precision medicine based on endotypes. We found that the CDHR3 gene, which is the receptor for rhinovirus C, is associated with a specific phenotype of adult asthma characterized by early-onset, atopic and decreased FEV1. We also found that the CHI3L1 gene encoding YKL-40, which is a negative regulator of inflammasome, is associated with adult-onset non-smoking asthma. Furthermore, we found that the TAM family receptor tyrosine kinase TYRO3, which is a negative regulator of type 2 immunity, is associated with allergic sensitization to common inhalant allergens or allergic rhinitis. These finding indicated the presence of endotypes each associated with increased susceptibility to viral infection, aberrant activation of inflammasome or increased susceptibility to allergic sensitization underlying asthma and COPD.
|
